{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T12:03:43Z","timestamp":1784721823547,"version":"3.55.0"},"reference-count":35,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Background: Breast cancer patients are exposed to cardiovascular complications related to both pre-existing cardiovascular risk factors and cardiotoxic cancer therapies. Heart failure with preserved ejection fraction (HFpEF) is an emerging and often under-recognized condition in this population, potentially present before treatment initiation and further influenced by oncologic therapies. This study aimed to characterize baseline HFpEF probability and its longitudinal evolution using validated scoring systems in a real-world cardio-oncology cohort. Methods: We retrospectively evaluated 145 women with breast cancer undergoing baseline cardio-oncology assessment before initiation of potentially cardiotoxic therapies. HFpEF probability was estimated using three validated algorithms (H2FPEF, ABA, and HFA-PEFF). A subgroup of 89 patients underwent exploratory reassessment after 12 \u00b1 3 months to investigate longitudinal changes in HFpEF probability according to treatment. Results: At baseline, HFpEF probability varied substantially according to the scoring system applied, with 14.8\u201341.5% of patients classified as having intermediate-to-high probability. Agreement among the three algorithms was limited, particularly between HFA-PEFF and H2FPEF\/ABA scores. Exploratory longitudinal analyses showed no significant changes in HFpEF probability categories during follow-up. Conclusions: HFpEF probability assessment in breast cancer patients showed substantial baseline heterogeneity across validated scoring systems, with clinically relevant differences in risk classification and limited inter-score agreement. These findings provide novel insights into an underexplored cardio-oncology phenotype and suggest that currently available HFpEF scoring systems may not be directly interchangeable in this clinical setting. Prospective studies including provocative testing are needed to determine the clinical relevance of HFpEF probability scores in breast cancer patients.<\/jats:p>","DOI":"10.3390\/jcm15145739","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T10:48:28Z","timestamp":1784717308000},"page":"5739","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Heart Failure with Preserved Ejection Fraction in Women with Breast Cancer Prior to Cancer Treatment: Insights from a Cardio-Oncology Assessment"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9195-5977","authenticated-orcid":false,"given":"Allegra","family":"Battistoni","sequence":"first","affiliation":[{"name":"Department of Clinical and Molecular Medicine, Sapienza University of Rome, 00185 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5634-1472","authenticated-orcid":false,"given":"Marco","family":"Di Francesco","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Medicine, Sapienza University of Rome, 00185 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Bernardo","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Medicine, Sapienza University of Rome, 00185 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacopo","family":"Capparelli","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Medicine, Sapienza University of Rome, 00185 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6659-5438","authenticated-orcid":false,"given":"Nicola","family":"Tartaglia","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Medicine, Sapienza University of Rome, 00185 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6910-9528","authenticated-orcid":false,"given":"Simona","family":"Pisegna","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Medicine, Sapienza University of Rome, 00185 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3409-5482","authenticated-orcid":false,"given":"Linda","family":"Piras","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Medicine, Sapienza University of Rome, 00185 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianmarco","family":"Cellammare","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Medicine, Sapienza University of Rome, 00185 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasqualino","family":"Raponi","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Medicine, Sapienza University of Rome, 00185 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"D\u2019Anna","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Medicine, Sapienza University of Rome, 00185 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Mistrulli","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Medicine, Sapienza University of Rome, 00185 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damiano","family":"Magr\u00ec","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Medicine, Sapienza University of Rome, 00185 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Barbato","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Medicine, Sapienza University of Rome, 00185 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.cardfail.2024.08.045","article-title":"Cardio-Oncology and Heart Failure: A Scientific Statement from the Heart Failure Society of America","volume":"31","author":"Bloom","year":"2025","journal-title":"J. Card. Fail."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"123170","DOI":"10.1016\/j.lfs.2024.123170","article-title":"Cardio-oncological dialogue: Understanding the mechanistic correlation between heart failure and cancer","volume":"358","author":"Bhat","year":"2024","journal-title":"Life Sci."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Lanza, O., Ferrera, A., Reale, S., Solfanelli, G., Petrungaro, M., Tini Melato, G., Volpe, M., and Battistoni, A. (2022). New Insights on the Toxicity on Heart and Vessels of Breast Cancer Therapies. Med. Sci., 10.","DOI":"10.3390\/medsci10020027"},{"key":"ref_4","unstructured":"ESC Scientific Document Group (2022). 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC). Eur. Heart J., 43, 4229\u20134361."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1002\/ejhf.70005","article-title":"Heart failure with preserved ejection fraction in cancer patients and survivors. A scientific statement of the Heart Failure Association of the ESC and the ESC Council of Cardio-Oncology","volume":"27","author":"Keramida","year":"2025","journal-title":"Eur. J. Heart Fail."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1161\/CIRCULATIONAHA.118.034646","article-title":"A Simple, Evidence-Based Approach to Help Guide Diagnosis of Heart Failure with Preserved Ejection Fraction","volume":"138","author":"Reddy","year":"2018","journal-title":"Circulation"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1093\/eurheartj\/ehz641","article-title":"How to Diagnose Heart Failure with Preserved Ejection Fraction: The HFA\u2013PEFF Diagnostic Algorithm","volume":"40","author":"Pieske","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1038\/s41591-024-03140-1","article-title":"An Evidence-Based Screening Tool for Heart Failure with Preserved Ejection Fraction: The HFpEF-ABA Score","volume":"30","author":"Reddy","year":"2024","journal-title":"Nat. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1038\/s41591-024-03154-9","article-title":"A simple tool to screen for heart failure with preserved ejection fraction","volume":"30","author":"Pandey","year":"2024","journal-title":"Nat. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.echo.2016.01.011","article-title":"Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"29","author":"Nagueh","year":"2016","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"ref_11","unstructured":"ESC Scientific Document Group (2021). 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J., 42, 3599\u20133726."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"103006","DOI":"10.1016\/j.jchf.2026.103006","article-title":"Effects of Finerenone on Heart Failure Outcomes According to Baseline Heart Failure Risk in Chronic Kidney Disease and Type 2 Diabetes","volume":"14","author":"Ostrominski","year":"2026","journal-title":"JACC Heart Fail."},{"key":"ref_13","unstructured":"World Health Organization (2026, June 09). Breast Cancer [Internet]; WHO Breast Cancer Fact Sheet, Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/breast-cancer."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1161\/CIRCULATIONAHA.115.020406","article-title":"Shared risk factors in cardiovascular disease and cancer","volume":"133","author":"Koene","year":"2016","journal-title":"Circulation"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/eurheartj\/ehab674","article-title":"Defining cardiovascular toxicities of cancer therapies: An International Cardio-Oncology Society (IC-OS) consensus statement","volume":"43","author":"Herrmann","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"ehae666.3161","DOI":"10.1093\/eurheartj\/ehae666.3161","article-title":"Does HFpEF represent a risk factor and a marker of cardiotoxicity in patients undergoing cancer treatment?","volume":"45","author":"Manderlier","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/ejhf.1920","article-title":"Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: A position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society","volume":"22","author":"Lyon","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A novel paradigm for heart failure with preserved ejection fraction: Comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.pcad.2024.07.002","article-title":"Anthracyclines, Diastolic Dysfunction and the Road to Heart Failure in Cancer Survivors: An Untold Story","volume":"86","author":"Camilli","year":"2024","journal-title":"Prog. Cardiovasc. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jcmg.2024.12.010","article-title":"Phenotypes of Myocardial Dysfunction on Serial Echocardiography and CMR in Women with Early-Stage Breast Cancer","volume":"18","author":"Huang","year":"2025","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_21","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/S0735-1097(17)34268-7","article-title":"Role of Diastolic Stress Testing in the Evaluation for Heart Failure with Preserved Ejection Fraction","volume":"69","author":"Obokata","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s10549-022-06586-4","article-title":"Risk of heart failure with preserved versus reduced ejection fraction in women with breast cancer","volume":"193","author":"Kwan","year":"2022","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ijcard.2020.05.084","article-title":"Blockade of the neurohormonal systems in heart failure with preserved ejection fraction: A contemporary meta-analysis","volume":"316","author":"Gallo","year":"2020","journal-title":"Int. J. Cardiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e07","DOI":"10.15420\/ecr.2021.62","article-title":"Dyspnoea in Oncological Patients: A Brain Teaser","volume":"18","author":"Keramida","year":"2023","journal-title":"Eur. Cardiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1161\/CIR.0000000000000556","article-title":"Cardiovascular Disease and Breast Cancer: Where These Entities Intersect. A Scientific Statement from the American Heart Association","volume":"137","author":"Mehta","year":"2018","journal-title":"Circulation"},{"key":"ref_27","first-page":"217","article-title":"Cardiovascular Risk and Level of Statin Use Among Women with Breast Cancer in a Cardio-Oncology Clinic","volume":"16","author":"Shum","year":"2016","journal-title":"Ochsner J."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"101209","DOI":"10.1016\/j.jacadv.2024.101209","article-title":"Under Pressure to Optimize the Cardiac Care of Breast Cancer Survivors","volume":"14","author":"Akhter","year":"2024","journal-title":"JACC Adv."},{"key":"ref_29","first-page":"322","article-title":"Cardiovascular Prevention Strategies in Breast Cancer","volume":"1","author":"Yin","year":"2019","journal-title":"J. Am. Coll. Cardiol. CardioOnc."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/ejhf.2017","article-title":"Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: A position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology","volume":"22","author":"Pudil","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1093\/eurjpc\/zwad146","article-title":"The underutilization of preventive cardiovascular measures in patients with cancer: An analysis of the Behavioural Risk Factor Surveillance System, 2011\u20132022","volume":"30","author":"Sayed","year":"2023","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa1209825","article-title":"Risk of Ischemic Heart Disease in Women After Radiotherapy for Breast Cancer","volume":"368","author":"Darby","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Yusuf, S.W., Venkatesulu, B.P., Mahadevan, L.S., and Krishnan, S. (2017). Radiation-Induced Cardiovascular Disease: A Clinical Perspective. Front. Cardiovasc. Med., 4.","DOI":"10.3389\/fcvm.2017.00066"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"k3845","DOI":"10.1136\/bmj.k3845","article-title":"Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: Systematic review","volume":"363","author":"Matthews","year":"2018","journal-title":"BMJ"},{"key":"ref_35","first-page":"2636","article-title":"Cardiovascular Disease Among Survivors of Adult-Onset Cancer: A Community-Based Retrospective Cohort Study","volume":"35","author":"Armenian","year":"2017","journal-title":"J. Clin. Oncol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/14\/5739\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T11:29:10Z","timestamp":1784719750000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/14\/5739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":35,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["jcm15145739"],"URL":"https:\/\/doi.org\/10.3390\/jcm15145739","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]}}}